Obesity News

The risk for all-cause mortality decreases among patients with knee or hip osteoarthritis who achieve slow-to-moderate, but not fast, weight loss via anti-obesity medications, according to data published in Arthritis & Rheumatology.

In the latest installment of Healio’s diversity, equity and inclusion video series with the ASGE, Catherine T. Hudson, MD, addressed how to combat emerging stigma around new anti-obesity medications such as glucagon-like peptide agonists.

Adults who reported high levels of perceived stress, particularly throughout early childhood, adolescence and early adulthood, were much more likely to develop cardiometabolic risk factors than those with low perceived stress, data show.

An increase in symptoms of depression was linked to a small increase in weight among adults with overweight or obesity, according to a recent study in PLOS One.

Preliminary results from an ongoing FDA investigation found no evidence that weight-loss drugs cause suicidal ideations and aspirations, although the agency said it cannot rule out a risk entirely.

Exposure to plastics containing endocrine-disrupting chemicals added an estimated $249 billion to health care costs in the U.S. in 2018, according to study data.

Adults receiving semaglutide as a type 2 diabetes or obesity medication have a lower risk for suicidal ideation than those who are using a drug that is not a GLP-1 receptor agonist, according to findings published in Nature Medicine.

In the landscape of health care, the year 2023 witnessed remarkable strides in the field of obesity medicine.

An FDA investigation of popular weight-loss drugs has generated a storm of media attention and prompted patient questions.

A low-carbohydrate diet that emphasized high-quality protein, fat and carbohydrates from healthful plant-based sources was linked to less weight gain over a 4-year period, according to a recent study.